<Anchor>



A corona vaccine made by a domestic pharmaceutical company has entered the final stage of development for the first time.



Including this vaccine, eight vaccines are currently undergoing clinical trials in Korea, and reporter Park Soo-jin pointed out whether they could be used next year.



<Reporter>



Public Vaccine Development Support Center in Osong, North Chungcheong Province.



400 samples from SK Bioscience's Phase 3 clinical trial for the COVID-19 vaccine have arrived.



Work is underway to measure how much neutralizing antibodies that neutralize the coronavirus are produced in the blood of clinical participants who have received the vaccine under development.



The final evaluation of vaccine effectiveness is a comparative clinical method that analyzes whether the effect is higher than that of control participants who received the AstraZeneca vaccine.



The evaluation results will be announced in March next year, and commercialization is targeted within the first half of the year.



[Kwon Jun-wook/Director of the National Institute of Health: The last stage clinical trial using a control vaccine is in progress. It is expected that a domestic vaccine will be available early next year after approval from the Ministry of Food and Drug Safety.] In



addition to this vaccine, there are 7 domestic vaccines in clinical trials, all of which are in phase 1 and 2 clinical trials.



In order to conduct comparative clinical trials, it is necessary to form a control group vaccinated with the existing vaccine.



[Pharmaceutical industry official: Everyone is unable to enter the clinical trial (Phase 3) because they can't solve it with a control vaccine.

Tha (A Pharmaceutical) even now there propulsion and (phase 3) control vaccine are (I know.) Geolro not obtained hageodeunyo in fact not be written to, not just for research trials.]



The European Medicines Agency is government purchases We have conditionally approved the contracted US Novavax vaccine.



The Ministry of Food and Drug Safety is also reviewing the approval of Novavax vaccine, which is being produced on consignment in Korea.



(Video coverage: Kim Min-cheol, video editing: Park Ji-in, CG: Choi Jae-young)